Loading
ADI-270 is an experimental CAR-T cell therapy from Adicet Therapeutics in phase 2 trials for renal cell carcinoma, aimed at CD70.
ADI-270 is a CAR-T cell therapy developed by Adicet Therapeutics. Its target is CD70 (the sponsor names CD70). The sponsor states: An armoured, allogeneic 'off-the-shelf' CAR gamma-delta (CAR-γδ) T-cell therapy directed against CD70-expressing cells, with reported CAR-directed and CAR-independent anti-tumour activity against solid and haematologic malignancies. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in renal cell carcinoma. The largest, NCT06480565, plans to enrol 60 participants with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
An armoured, allogeneic 'off-the-shelf' CAR gamma-delta (CAR-γδ) T-cell therapy directed against CD70-expressing cells, with reported CAR-directed and CAR-independent anti-tumour activity against solid and haematologic malignancies. Connects to CD70.
1.ADI-270 slips into a pocket on CD70.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ADI-270" OR ABSTRACT:"ADI-270") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ADI-270, not a curated reading list.
Shares CD70 and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.